SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* FLEMING JONATHAN (Last) (First) (Middle) C/O OXFORD BIOSCIENCE PARTNERS 222 BERKELEY STREET, SUITE 1650 (Street) BOSTON MA 02116 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol IMCOR PHARMACEUTICAL CO [ ICPHC ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 04/14/2004
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/14/2004		P		2,933,334(2)	A	$0.75	9,414,816	I	By Oxford Bioscience Partners IV L.P. and MRNA Fund II L.P.(1)
Common Stock	04/14/2004		P		5,200,464(3)	A	$0.75	14,615,280	I	By Oxford Bioscience Partners IV L.P. and MRNA Fund II L.P.(1)
Common Stock	04/19/2004		P		11,693,887(4)(5)	A	$0.75	26,309,167	I	By Oxford Bioscience Partners IV L.P. and MRNA Fund II L.P.(1)
Revolving Convertible Senior Secured Promissory Notes	04/14/2004		S		3,900,348(3)	D	$0.75	0	I	By Oxford Bioscience Partners IV L.P. and MRNA Fund II L.P.(1)
Secured Promissory Notes	04/19/2004		S		8,770,415.43(4)(5)	D	$0.75	0	I	By Oxford Bioscience Partners IV L.P. and MRNA Fund II L.P.(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants to purchase common stock	$1	04/14/2004		P		1,466,668(6)		04/14/2004	04/14/2009	Common Stock	1,466,668	$0	1,466,668	I	By Oxford Bioscience Partners IV L.P. and MRNA Fund II L.P.

1. Name and Address of Reporting Person* FLEMING JONATHAN (Last) (First) (Middle) C/O OXFORD BIOSCIENCE PARTNERS 222 BERKELEY STREET, SUITE 1650 (Street) BOSTON MA 02116 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer X Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* OBP MANAGEMENT IV LP (Last) (First) (Middle) 222 BERKELEY STREET, SUITE 1650 (Street) BOSTON MA 02116 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

Explanation of Responses:

1. Jonathan Fleming is the general partner of OBP Management IV L.P., which is the general partner of both Oxford Bioscience Partners IV L.P. ("Oxford") and MRNA Fund II L.P ("MRNA"). As such Mr. Fleming and OBP Management IV L.P. disclaim beneficial ownership except to the extent of their pecuniary interests.

2. On April 14, 2004, Oxford and MRNA agreed to purchase an aggregate of 2,933,334 shares of common stock, 568,678 shares were issued to Oxford and 5,706 were issued to MRNA at the initial closing on April 19, 2004. In connection with the second closing to occur no later than July 19, 2004, an additional 2,335,517 shares will be issued to Oxford and an additional 23,433 will be issued to MRNA.

3. On April 14, 2004, Oxford and MRNA agreed to convert convertible notes in the aggregate amount of $3,900,348. Of the aggregate amount of $3,900,348, Oxford agreed to convert principal of $3,623,644 and interest of $237,957.50, at a conversion price of $0.75 per share, which resulted in the acquisition of 5,148,802 shares of common stock. Of the aggregate amount of $3,900,348, MRNA agreed to convert principal of $36,356 and interest of $2,390.50, at a conversion price of $0.75 per share, which resulted in the acquisition of 51,662 shares of common stock. The convertible notes were convertible into common stock at a conversion price equal to the price of the common stock in a qualified equity financing at the same price on the same terms as securities sold to investors in such qualified equity financing.

4. On April 19, 2004, Oxford and MRNA agreed to convert secured notes in the aggregate amount of $8,770,415.43. Of the aggregate amount of $8,770,415.43, Oxford agreed to convert principal of $8,239,373.33 and interest of approximately $457,174.56, at a conversion price of $0.75 per share. The conversion of the principal of Oxford's secured notes will result in the acquisition of 10,985,831 shares of common stock and the conversion of the interest of Oxford's secured notes will result in the acquisition of approximately 609,566 shares of common stock. (continued in footnote 5)

5. Of the aggregate amount of $8,770,415.43, MRNA agreed to convert principal of $70,126.67 and interest of approximately $3,740.87, at a conversion price of $0.75 per share. The conversion of the principal of MRNA's secured notes will result in the acquisition of 93,502 shares of common stock and the conversion of the interest will result in the acquisition of approximately 4,987 shares of common stock. The secured notes became convertible pursuant to a securities purchase agreement entered into on April 19, 2004. The closing of the conversion of secured notes will occur no later than July 19, 2004.

6. On April 14, 2004, Oxford and MRNA agreed to purchase warrants to purchase an aggregate of 1,466,668 shares of common stock, warrants to purchase 284,339 shares of common stock were issued to Oxford and warrants to purchase 2,853 shares of common stock were issued to MRNA at the initial closing on April 19, 2004. In connection with a second closing to occur no later than July 19, 2004, warrants to purchase an additional 1,167,759 shares will be issued to Oxford and warrants to purchase an additional 11,717 shares of common stock will be issued to MRNA.

	/s/ Jonathan Fleming	06/17/2004
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.